Humana Inc. (NYSE:HUM) Shares Sold by Quantinno Capital Management LP

Quantinno Capital Management LP trimmed its position in Humana Inc. (NYSE:HUM) by 64.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,204 shares of the insurance provider’s stock after selling 13,126 shares during the quarter. Quantinno Capital Management LP’s holdings in Humana were worth $2,282,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of HUM. Pzena Investment Management LLC boosted its holdings in Humana by 538.7% in the 2nd quarter. Pzena Investment Management LLC now owns 2,318,347 shares of the insurance provider’s stock valued at $866,250,000 after purchasing an additional 1,955,375 shares during the last quarter. Marshall Wace LLP boosted its holdings in Humana by 118.9% in the 2nd quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider’s stock valued at $532,564,000 after purchasing an additional 774,085 shares during the last quarter. International Assets Investment Management LLC boosted its holdings in Humana by 261,025.1% in the 3rd quarter. International Assets Investment Management LLC now owns 738,984 shares of the insurance provider’s stock valued at $2,340,660,000 after purchasing an additional 738,701 shares during the last quarter. FMR LLC boosted its holdings in Humana by 23.4% in the 3rd quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock valued at $1,073,387,000 after purchasing an additional 643,291 shares during the last quarter. Finally, Baupost Group LLC MA acquired a new position in Humana in the 2nd quarter valued at about $156,933,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Stock Down 0.1 %

Shares of NYSE:HUM opened at $285.82 on Wednesday. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. The company has a fifty day simple moving average of $272.07 and a 200 day simple moving average of $326.37. The firm has a market cap of $34.42 billion, a PE ratio of 25.32, a price-to-earnings-growth ratio of 2.18 and a beta of 0.53. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $488.89.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, topping analysts’ consensus estimates of $3.48 by $0.68. Humana had a net margin of 1.18% and a return on equity of 13.20%. The firm had revenue of $29.30 billion during the quarter, compared to the consensus estimate of $28.66 billion. On average, equities research analysts anticipate that Humana Inc. will post 16.14 EPS for the current fiscal year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.24%. The ex-dividend date of this dividend is Tuesday, December 31st. Humana’s dividend payout ratio (DPR) is presently 31.36%.

Analyst Ratings Changes

A number of research firms have recently issued reports on HUM. Leerink Partners downgraded shares of Humana from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $400.00 to $250.00 in a research note on Wednesday, October 2nd. Wells Fargo & Company lowered their price target on shares of Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a report on Monday, November 4th. UBS Group lowered their target price on shares of Humana from $380.00 to $250.00 and set a “neutral” rating for the company in a report on Friday, October 4th. JPMorgan Chase & Co. upped their target price on shares of Humana from $332.00 to $396.00 and gave the company a “neutral” rating in a report on Wednesday, August 21st. Finally, Piper Sandler cut shares of Humana from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $392.00 to $274.00 in a research note on Thursday, October 3rd. Twenty investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $315.86.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.